Juhani Saarinen
Chief Executive Officer Glykos
Seminars
Tuesday 13th October 2026
Targeting Solid Tumors & Hematological Malignancies With Mono & Dual Payload ADCs Utilizing Auristatin, Topo1 & Novel Modality Payloads
2:30 pm
- Developing a hydrophilic linker with optimized cleavable moiety to enable efficient auristatin, exatecan and novel linker-payloads for ADCs
- Showing DAR4 and DAR8 MMAU auristatin ADCs with outstanding therapeutic window against solid tumors and hematological malignancies
- Utilizing optimized linker and conjugation technologies for dual payload ADCs
